Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16317148 | 0.88 | ALDH1A1 (0.52) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL4050492 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2080468 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2081991 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2083765 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2082551 | 0.80 | SMN1; SMN2 (0.58) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL2474225 | 0.78 | RAB9A (0.58) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 | |
| SCHEMBL3024153 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL14357218 | 0.78 | KMT2A (0.55) | ALDH1A1TSHRSMN1; SMN2LMNAPDE4D | |
| SCHEMBL11687153 | 0.77 | POLB (0.43) | ALDH1A1TSHRSMN1; SMN2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | ALDH1A1 1743/4885TSHR 584/4885SMN1; SMN2 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.